Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
Colorado Blood Cancer Network, Denver, Colorado University of Maryland, Greenbaum Comprehensive Cancer Center, Baltimore, Maryland Dana Farber Cancer Institute, Boston, Massachusetts START - Midwest, Grand Rapids, Michigan Washington University School of Medicine, St Louis, Missouri Duke University Medical Center, Durham, North Carolina South Austin Medical Center, Austin, Texas